14 October 2022>: Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint 12ABCDEFG* , Jill M. Kolesar 23CDE , Joseph Robert McCorkle 2CDE , Jianrong Wu 4C , Carleton S. Ellis 23CDE , Danielle E. Otto 23CDE , Peng Wang 12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 1 Patient baseline characteristics.
Characteristics | # (Range) | % |
---|---|---|
Total patients enrolled | 13 | |
Median age, years (range) | 64 (56–83) | |
Ethnicity | ||
White | 11 | 85% |
African-American | 2 | 15% |
Median body mass index, kg/m (range) | 30.1 (20.7–38.7) | |
Obese | 8 | 62% |
Non-obese | 5 | 38% |
ECOG performance status | ||
0 | 4 | 31% |
1 | 6 | 46% |
2 | 3 | 23% |
Received previous treatment | ||
Yes | 3 | 23% |
No | 10 | 77% |
Median PSA (ng/mL) (range) | 132 (57–4279) | |
Volume of disease | ||
High | 10 | 77% |
Low | 3 | 23% |
ECOG – Eastern Cooperative Oncology Group; PSA – prostate-specific antigen; # – number. |